Department of Psychiatry, Service of psychiatric specialties, Mood disorder unit, Geneva University Hospitals, Rue de Lausanne 20, CH-1201, Geneva, Switzerland; Division of Clinical Pharmacology and Toxicology, Department of Anesthesiology, Psychopharmacology Unit, Geneva University Hospitals, Geneva, Switzerland.
Division of Clinical Pharmacology and Toxicology, Department of Anesthesiology, Psychopharmacology Unit, Geneva University Hospitals, Geneva, Switzerland; Division of Clinical Pharmacology and Toxicology, Department of Anesthesiology, Intensive care and Pharmacology, Multidisciplinary Pain Center, Geneva University Hospitals, Geneva, Switzerland.
Psychiatry Res. 2021 Nov;305:114193. doi: 10.1016/j.psychres.2021.114193. Epub 2021 Aug 28.
Gabapentinoids and opioids have in common that they are used in medicine in the treatment of pain, and by addicts in recreational use. In recent years, in the context of the "opioid epidemics", gabapentinoids, which had a reputation for low risk of abuse, have been increasingly prescribed. This was accompanied by increasingly frequent abuses, the patients most at risk being those suffering from opiate addiction. However, gabapentinoids increase the risks associated with opioids or other sedatives, due to a synergy of central depressant effects. This leads to reconsider the framework of their prescription and the management of chronic pain.
加巴喷丁类药物和阿片类药物的共同点是它们都被用于医学上治疗疼痛，并且被瘾君子用于娱乐性使用。近年来，在“阿片类药物流行”的背景下，加巴喷丁类药物因其滥用风险低而被越来越多地开处方。随之而来的是滥用行为越来越频繁，风险最大的是那些患有阿片类药物成瘾的患者。然而，加巴喷丁类药物会增加与阿片类药物或其他镇静剂相关的风险，因为它们具有中枢抑制作用的协同效应。这导致人们重新考虑它们的处方框架和慢性疼痛的管理。
